Erika Lietzan is a professor at the University of Missouri School of Law. Her primary research focus lies at the intersection of intellectual property law and FDA regulation of medical products. Her scholarship has focused on the new drug research and development paradigm and its impact on incentives to innovate, innovation and competition in the marketplace for biological medicines, the incentive for generic drug applicants to challenge innovator patents, data exclusivity for drug and biological medicine innovators, and mandatory public disclosure of clinical data in drug applications, among other issues. Professor Lietzan brings to her scholarship and teaching eighteen years of private practice experience, eight of them as a partner at Covington & Burling in Washington, DC. She blogs at

Recent Posts by Erika Lietzan

Sandoz v. Amgen: What The Court Settled, What It Didn’t, And What Might Come Next

On June 12, the Supreme Court ruled that biosimilar companies will generally be able to launch their product as soon as the data exclusivity on the innovative product expires. In simple terms, this translates to cheaper medicines sooner. On a second issue, the outcome was more complex.